

Parsabiv - (2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL; Solution, Intravenous)

Generic Name	Etelcalcetide	Innovator	Amgen
Dosage	2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL; Solution, Intravenous	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	PARSABIV is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.